Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are the two most prominent incretin-based metabolic drugs, and both are FDA-approved for diabetes and weight management. The key structural difference is that semaglutide targets one incretin receptor while tirzepatide targets two. This comparison summarizes their mechanisms, trial outcomes, and dosing as reported in the literature.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | GLP-1 receptor agonist (single incretin) | Dual GIP and GLP-1 receptor agonist |
| Primary mechanism | Activates GLP-1 receptors to boost insulin, slow gastric emptying, and reduce appetite | Activates both GIP and GLP-1 receptors for a combined incretin effect |
| Approval status / brands | FDA-approved: Ozempic and Rybelsus (diabetes), Wegovy (weight) | FDA-approved: Mounjaro (diabetes), Zepbound (weight) |
| Reported weight loss (trials) | ~15% average at 2.4 mg over ~68 weeks (STEP program) | Up to ~21% at the top dose over ~72 weeks (SURMOUNT program) |
| Reported dosing / titration | Titrated to 2.4 mg weekly (injectable) or up to 14 mg oral daily | Titrated from 2.5 mg up to 15 mg weekly |
| Route / frequency | Once-weekly subcutaneous injection, or once-daily oral | Once-weekly subcutaneous injection |
| Reported half-life | ~7 days (supports once-weekly dosing) | ~5 days (supports once-weekly dosing) |
| Common side effects | GI-predominant: nausea, diarrhea, constipation; slow titration reduces them | Similar GI profile; slow titration advised |
Semaglutide
Semaglutide is the best-studied single GLP-1 agonist, approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management, with trial-average weight loss around 15%.
Full Semaglutide profile →Tirzepatide
Tirzepatide is a dual GIP/GLP-1 agonist approved as Mounjaro and Zepbound, with trial and head-to-head data showing greater average weight loss — up to roughly 21% at the highest dose.
Full Tirzepatide profile →The bottom line
In trials tirzepatide has produced larger average weight loss than semaglutide, but both are prescription medicines that require medical supervision and slow dose titration to manage gastrointestinal side effects, and individual response varies. The ‘better’ option depends on the patient, tolerability, and clinical goals, which is a decision for a prescriber. This is educational information, not medical advice.
Educational summary only. Dosing and effects describe how these compounds appear in the research literature — not a recommendation for human use. For laboratory research use only.
Semaglutide vs Tirzepatide FAQ
What is the difference between semaglutide and tirzepatide?
Semaglutide activates a single incretin receptor (GLP-1), while tirzepatide activates two (GIP and GLP-1). Both slow gastric emptying and reduce appetite, but the dual mechanism of tirzepatide is associated with greater average weight loss in trials.
Is tirzepatide better than semaglutide for weight loss?
In clinical trials and a head-to-head study (SURMOUNT-5), tirzepatide produced greater average weight loss — roughly 21% at the top dose versus about 15% for semaglutide. ‘Better’ still depends on the individual, tolerability, cost, and clinical judgment, so this is a decision for a prescriber, not medical advice.
Are semaglutide and tirzepatide approved?
Yes. Semaglutide is FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management; tirzepatide is approved as Mounjaro for diabetes and Zepbound for weight management.
How are semaglutide and tirzepatide dosed?
Both are once-weekly injections that are titrated slowly to limit nausea and other GI effects — semaglutide up to 2.4 mg weekly (an oral daily form also exists), and tirzepatide from 2.5 mg up to 15 mg weekly. Actual dosing is set by a prescriber.